<DOC>
	<DOCNO>NCT00053092</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Monoclonal antibody rituximab locate cancer cell either kill deliver cancer-killing substance without harm normal cell . It yet know combination chemotherapy effective without rituximab treat mantle cell lymphoma . PURPOSE : Randomized phase II trial compare effectiveness fludarabine cyclophosphamide combine rituximab fludarabine cyclophosphamide alone treat patient mantle cell lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Rituximab Treating Patients With Mantle Cell Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Compare response rate patient previously untreated mantle cell lymphoma treat fludarabine cyclophosphamide without rituximab . - Compare time disease progression patient treat regimen . - Compare toxicity regimen , term adverse event profile , patient . - Compare overall survival patient treat regimen . OUTLINE : This randomize , open-label , multicenter study . Patients randomize 1 2 treatment arm : - Arm I : Patients receive fludarabine IV* cyclophosphamide IV* day 1-3 . - Arm II : Patients receive rituximab IV day 1 fludarabine IV* cyclophosphamide IV* day 2-4 . NOTE : *In arm , fludarabine cyclophosphamide may administer orally instead IV . Treatment repeat every 28 day 2-8 course absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 56-82 patient ( 28-41 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm previously untreated mantle cell lymphoma require therapy Any stage PATIENT CHARACTERISTICS : Age 18 Performance status Not specify Life expectancy At least 3 month Hematopoietic Not specify Hepatic Bilirubin great 2.5 time upper limit normal ( ULN ) ^* Alkaline phosphatase great 2.5 time ULN^* Hepatitis B hepatitis C negative NOTE : *Unless related lymphoma Renal Creatinine great 2.5 time ULN^* NOTE : *Unless relate lymphoma Other No malignancy within past 5 year except nonmelanoma skin cancer curatively resect carcinoma situ cervix No prior psychological illness condition would preclude study compliance No known hypersensitivity murine proteins No concurrent uncontrolled medical condition No illness would severely limit life expectancy HIV negative Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month study participation PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>contiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>stage I mantle cell lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
</DOC>